Bio-Techne Announces Publication of Lateral Flow Technology Proof-of-Concept Data

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced a significant breakthrough with the publication of a manuscript in Scientific Reports demonstrating their lateral flow technology for COVID-19 diagnostics. The proof-of-concept study shows an affordable test using a minimally invasive swab that yields results in 15 minutes, featuring 87.5% sensitivity and 100% specificity. The company aims to collaborate with diagnostic firms to further develop rapid diagnostic tests leveraging their extensive resources.

Positive

• Published proof-of-concept manuscript validates proprietary lateral flow technology for COVID-19 testing.
• Test offers 87.5% sensitivity and 100% specificity, enabling efficient diagnosis with rapid results.
• Plans to collaborate with diagnostic companies for future test development enhance business prospects.

Negative

• None.

MINNEAPOLIS, Dec. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of an important manuscript in the journal Scientific Reports, a Nature Research journal, showing proof-of-concept of its proprietary lateral flow technology. The manuscript is entitled SARS-CoV-2 antigen rapid diagnostic test for resource limited settings. In this manuscript, Bio-Techne scientists demonstrate a method for developing an inexpensive alternate test for diagnosing active COVID-19 infection caused by SARS-CoV-2 with a minimally invasive anterior nares swab sample.

The paper discusses a proof-of-concept lateral flow-based test that identifies the presence of the SARS-CoV-2 antigen with no equipment or laboratory infrastructure to administer. The test rapidly produces results after 15 minutes with a limit of detection of 2.0 x 10² TCID₅₀/mL, 87.5% sensitivity, and 100% specificity.

"This manuscript clearly demonstrates the power of our proprietary lateral flow technology," said Chuck Kummeth, President and Chief Executive Officer. "We are looking forward to leveraging this technology while supporting our OEM partnerships going forward."

Bio-Techne intends to utilize its vast collection of proteins, antibodies, and technologies to partner with diagnostic companies to develop additional rapid diagnostic tests and offer custom design and development services for lateral flow assay reagents, test development, and manufacturing.

This is the second publication on Bio-Techne's lateral flow initiatives this year, following the first paper entitled "Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs" published in the journal of Diagnostics, 2021, 11, 1190. This paper demonstrated that lateral flow immunoassay could be a rapid and effective tool for antibody characterization, including epitope classification and surrogate antibody neutralization kinetics.

About Bio-Techne Corporation (NASDAQ: TECH)

Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-publication-of-lateral-flow-technology-proof-of-concept-data-301439995.html

SOURCE Bio-Techne Corporation

FAQ

What did Bio-Techne announce on December 8, 2021?

Bio-Techne announced the publication of a manuscript demonstrating the proof-of-concept for their lateral flow technology for COVID-19 diagnostics.

What are the key features of the lateral flow test developed by Bio-Techne?

The test is inexpensive, requires a minimally invasive swab, provides results in 15 minutes, and has 87.5% sensitivity and 100% specificity.

How does Bio-Techne plan to utilize its lateral flow technology?

Bio-Techne intends to partner with diagnostic companies to develop additional rapid diagnostic tests using their proprietary technology.

Where was the proof-of-concept research published?

The proof-of-concept research was published in the journal Scientific Reports.